Important Safety Information
Stanozolol carries significant hepatotoxic potential as a 17-alpha-alkylated anabolic steroid. Prolonged high-dosage use has been associated with peliosis hepatis (blood-filled cysts in the liver), hepatic neoplasms, and hepatocellular carcinoma. Cholestatic jaundice and elevated liver enzymes (GOT, GPT) have been reported, and periodic liver function testing is recommended during therapy.
Stanozolol can cause blood lipid changes known to increase cardiovascular risk, including decreased HDL and sometimes increased LDL cholesterol. Anabolic steroids may also increase sensitivity to anticoagulants, potentially requiring dose adjustment of blood thinners.
Important
Non-Medical Use
Stanozolol's approved medical indication was limited to hereditary angioedema, and the human oral product is now discontinued in the USA. The FDA labeling states that anabolic steroids have not been shown to enhance athletic ability. Use for bodybuilding or performance enhancement falls outside approved medical indications and is associated with significant health risks.
Potential Adverse Effects
Commonly reported side effects of stanozolol include acne, changes in libido, and headaches. In women, virilization effects such as deepening of the voice, hirsutism, acne, and clitoral enlargement may occur, and some changes may be irreversible. In men, stanozolol can suppress endogenous testosterone production and cause gynecomastia, acne, and testicular dysfunction.
Serious adverse effects include liver toxicity, blood lipid changes, and fluid retention. Stanozolol is contraindicated in pregnancy and can cause birth defects. It should be used with caution in patients with diabetes, heart disease, kidney disease, or liver impairment.
Conditions Requiring Medical Evaluation
Stanozolol is contraindicated in patients with prostate cancer, breast cancer in males, hypercalcemia, or porphyria. It should be used with caution in patients with pre-existing cardiac, renal, or hepatic disease, hypertension, epilepsy, migraines, or diabetes.
Women who are pregnant or breastfeeding should not use stanozolol. Individuals planning to have children should discuss potential fertility effects with a healthcare professional.
Monitoring During Therapy
Medical stanozolol therapy typically involves periodic liver function tests due to hepatotoxicity potential. Lipid profiles and hemoglobin/hematocrit may also be monitored. Blood glucose should be monitored in diabetic patients.
Laboratory testing of the product itself, such as a published potency report, is separate from clinical monitoring of the person using stanozolol. No published laboratory report is available for this specific product.
Product Care
Storage & Handling
Store in a closed container at room temperature, away from heat, moisture, and direct light. Keep all medications out of the reach of children. Follow the storage instructions provided with the product packaging.
Further Safety Information